Onconetix (ONCO) Non-Current Assets (2021 - 2026)
Onconetix (ONCO) posted quarterly Non-Current Assets of $10.5 million for Q1 2026, down 35.78% year-over-year from $16.4 million in Q1 2025, and down 44.31% quarter-over-quarter from $18.9 million in Q4 2025.
Onconetix (ONCO) Non-Current Assets (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Non-Current Assets for 6 consecutive years, with $10.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 35.78% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $65.9 million (up 33.52% YoY), while the FY2025 annual figure was $18.9 million, down 30.74% from the prior year.
- Non-Current Assets eased to $10.5 million in Q1 2026 per ONCO's latest filing, from $18.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $81.7 million in Q4 2023 and bottomed at -$29.2 million in Q3 2022.
- Historically, Non-Current Assets has averaged $13.1 million across 5 years, with a median of $10.5 million in 2026.
- Annual changes were most pronounced in 2022 — Non-Current Assets plunged 220909.75% — and 2024, when it surged 231259.48%.
- Onconetix's Non-Current Assets stood at -$25.4 million in 2022, then soared by 421.61% to $81.7 million in 2023, then tumbled by 66.66% to $27.2 million in 2024, then tumbled by 30.74% to $18.9 million in 2025, then plunged by 44.31% to $10.5 million in 2026.
- Business Quant data shows ONCO's Non-Current Assets at $10.5 million in Q1 2026, $18.9 million in Q4 2025, and $18.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 9.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.91 Mn |
| Mar 31, 2026 | 10.50 Mn |
| Dec 31, 2025 | 18.86 Mn |
| Sep 30, 2025 | 18.38 Mn |
| Jun 30, 2025 | 18.19 Mn |
| Mar 31, 2025 | 16.36 Mn |
| Dec 31, 2024 | 27.23 Mn |
| Sep 30, 2024 | 826,838.00 |
| Jun 30, 2024 | 4.96 Mn |
| Mar 31, 2024 | 68.74 Mn |
| Dec 31, 2023 | 81.68 Mn |
| Sep 30, 2023 | -6.93 Mn |
| Jun 30, 2023 | 18.34 Mn |
| Mar 31, 2023 | 29,710.00 |
| Dec 31, 2022 | -25.40 Mn |
| Sep 30, 2022 | -29.19 Mn |
| Jun 30, 2022 | 119,342.00 |
| Mar 31, 2022 | 232,491.00 |
| Dec 31, 2021 | 11,502.00 |